| 查看: 427 | 回复: 1 | ||
[资源]
职业发展 白皮书- The continuing evolution of the Pharmaceutical Industry
|
|
RegentAtlantic Capital, LLC is pleased to present our white paper entitled “The Continuing Evolution of the Pharmaceutical Industry: Career Challenges and Opportunities”. http://www.pharmawealthmanager.c ... Y%20Nov-30-2007.pdf The Continuing Evolution of the Pharmaceutical Industry: Career Challenges and Opportunities December 2007 Michael Steiner, CFP®, CPA David H. Bugen, CFP®, MBA Brian Kazanchy, CFP®, CFA, MBA William T. Knox IV, CFP®, CFA, JD Margaret V. Prentice, MBA Lauren Goldfarb Mark P. Hurley Steven E. Cortez Christine L. Boudreaux Benjamin J. Robins Yvonne N. Kanner Shehzad Sippy Adam L. Bartkoski Ana M. Avila are Changing the Industry and the Careers of its Participants ............................................................. 3 Revenues are Under Pressure ................................................. 3 Costs and Risks of Developing New Drugs are Increasing ....... 3 Globalization ............................................................................ 4 Big Changes for the Pharmaceutical Industry .................................. 4 Corporate Restructuring .......................................................... 5 Adoption of Risk Reduction Strategies ..................................... 5 Evolution of Drug Marketing ..................................................... 6 What Does it all Mean to an Industry Professional? .......................... 6 Six Future High Growth Areas of the Industry .................................. 6 Commercialization of Dormant Compounds ............................ 7 Generic or Biosimilar Versions of Biologics .............................. 7 Improving the Effi ciency of R&D ............................................... 7 Oncology and Central Nervous System (CNS) Disorders Research ......................................................... 7 Stratifi ed Medicine and Diagnostics ......................................... 7 Fusion of Pharmaceuticals and Consumer Goods ................... 8 Seven Highly-Valued Skill Sets ......................................................... 8 Ability to Manage Decentralized Intellectual Capital Resources .....8 Ability to Work in Joint Ventures and Across Divisions, Cultures and Countries.................................................... 8 Ability to Integrate an Understanding of Intellectual Property Laws, Scientifi c Expertise and Business Strategy ..................................................... 9 Ability to Spur Creativity While Managing Commercially ........... 9 Knowledge and Insight on the Decision-Making Dynamics of Payers ........................................................ 9 Expertise in the Functioning and Decision-Making of Regulatory Agencies ................................................. 10 Human Resource Skills to Help Transform Pharmaceutical Companies ................................................................... 10 Every Industry Participant will Experience Change ......................... 10 Conclusion .................................................................................... 11 II. An Industry Forced to Change ................................ 12 Forces Shaping the Pharmaceutical Industry ................................. 12 Industry Revenues are Under Pressure .................................. 12 Costs and Risks are Increasing .............................................. 23 Globalization .......................................................................... 27 Big Changes for the Pharmaceutical Industry ................................ 30 Limited and Unattractive Choices .......................................... 30 Changes Have Already Begun ............................................... 31 Dislocation of a Generation of Upper-Middle and Senior-Level Executives ................................................. 32 Mergers and Acquisitions as a Cost-Cutting Strategy ............ 33 Refocused Strategies with Fewer Treatment Lines ................. 35 Acquiring Instead of Developing Compounds ........................ 36 Research Consortiums Share Risk ......................................... 37 Outsourcing of R&D to Foreign Laboratories .......................... 38 Evolution of Marketing ........................................................... 38 A Very Different Industry ................................................................ 40 III. Opportunities for the Next Decade ......................... 42 A New Golden Era ......................................................................... 42 Six High-Growth Areas .................................................................. 43 Commercialization of Dormant Compounds .......................... 43 Generic or Biosimilar Versions of Biologics ............................ 44 Improving the Effi ciency of R&D ............................................. 47 Oncology and Central Nervous System (CNS) Disorders Research ....................................................... 48 Stratifi ed Medicine and Diagnostics ....................................... 50 Fusion of Pharmaceuticals and Consumer Goods ................. 51 Seven Skill Sets with Great Future Value ........................................ 52 Ability to Manage Decentralized Intellectual Capital Resources .......................................................... 52 Ability to Work in Joint Ventures and Across Divisions, Cultures and Countries.................................................. 53 Ability to Integrate an Understanding of Intellectual Property Laws, Scientifi c Expertise and Business Strategy ................................................... 54 Ability to Spur Creativity While Managing Commercially ......... 55 Knowledge and Insight on the Decision-Making Dynamics of Payers ....................................................................... 57 Expertise in the Functioning and Decision-Making of Regulatory Agencies ..................................................... 58 Human Resource Skills to Help Transform Pharmaceutical Companies ................................................................... 59 IV. Planning Your Future ................................................ 60 Step 1: Taking Responsibility for Your Career Planning .................. 60 Step 2: Assessing the Industry’s Future Structure and Your Tolerance for Risk ........................................................ 61 The Shifting Structure of the Pharmaceutical Industry ............ 61 Cultures Vary by Size of Enterprise ........................................ 62 The Risk vs. Reward Calculus ................................................ 65 Step 3: Evaluating Your Financial Resources and the Economic Impact of a Career Change ........................................ 67 Evaluating Your Asset Allocation and the Concentration Risk Borne by Many in the Pharmaceutical Industry .............. 69 Leaving an Employer Will Often Involve Hidden Costs ............ 72 Understanding Risks Involved in Taking a New Job ................ 77 Step 4: Figuring Out Who You Are and How to Brand Yourself ...... 82 Athletes vs. Specialists .......................................................... 82 Developing a Personal Branding Strategy .............................. 84 A Final Thought: Begin with a Comprehensive Self-Assessment .... 86 V. Conclusion ................................................................ 87 VI. Appendix.................................................................... 88 |
回复此楼» 猜你喜欢
中国药科大学2026入学博士，药物合成和设计经验，放射化学及放射医学研究
已经有25人回复
-
使用MolAICal进行多肽虚拟筛选教程-同样适用于蛋白质和核酸的虚拟筛选
已经有1人回复
-
药物学论文润色/翻译怎么收费?
已经有139人回复
-
使用MolAICal计算药物化学过滤器MCFs及MCE-18描述符
已经有0人回复
-
使用MolAICal发现蛋白受体潜在的活性口袋及位点
已经有0人回复
-
华理药学学硕求调剂，总分324
已经有0人回复
-
广西医科大学基础医学院自身免疫病课题组招收基础医学相关专业的调剂研究生
已经有2人回复
-
澳门理工大学人工智能药物发现中心招收2026级博士研究生（申请-考核制）
已经有10人回复
2楼2013-12-20 12:24:28
10